LE WE PMID CA
Neoplasia (PET)5989Neubildung (PET)

MRT (DCE MRI)

MRT (Instrumentation)

Neoplasia (Imaging)

Neoplasia (MRS)

Neoplasia (MRT)

Neoplasia (PET)

Neoplasia (Unknown primary tumor)

Positron emission tomography (Method)

Radiation therapy

2002  
1
The value of positron emission tomography (PET) imaging in disease staging and therapy assessment.
[12401695] Ann Oncol 13 Suppl 4(-): 227-34 (2002)
1993  
2
Clinical applications of positron-emission tomography in cancer.
[8324656] CA Cancer J Clin 43(4): 235-54 (1993)
2007  
3
Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond.
[17575208] Clin Cancer Res 13(12): 3460-9 (2007)
2006  
4
Present role and future prospects of positron emission tomography in clinical oncology.
[17052261] Cancer Sci 97(12): 1291-7 (2006)
2006  
5
18FDG PET in oncology: the best and the worst (Review).
[16596242] Int J Oncol 28(5): 1249-61 (2006)
2007  
6
Brain abnormalities detected on whole-body 18F-FDG PET in cancer patients: spectrum of findings.
[17312080] AJR Am J Roentgenol 188(3): 866-73 (2007)
2001  
7
From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.
[11831394] Ann Nucl Med 15(6): 471-86 (2001)
2002  
8
Clinical applications of (18)F-FDG in oncology.
[11948260] J Nucl Med Technol 30(1): 3-9; quiz 10-1 (2002)
2009  
9
18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.
[19837767] J Nucl Med 50(11): 1820-7 (2009)
2009  
10
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
[19403881] J Nucl Med 50 Suppl 1(-): 122S-50S (2009)
2009  
11
18F-FDG PET and PET/CT in the evaluation of cancer treatment response.
[19139187] J Nucl Med 50(1): 88-99 (2009)
2008  
12
PET imaging of cancer immunotherapy.
[18511842] J Nucl Med 49(6): 865-8 (2008)
2008  
13
Recommendations on the use of 18F-FDG PET in oncology.
[18287273] J Nucl Med 49(3): 480-508 (2008)
2008  
14
18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.
[18077527] J Nucl Med 49(1): 13-21 (2008)
2008  
15
18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
[18077522] J Nucl Med 49(1): 9-12 (2008)
2007  
16
Clinical applications of PET in brain tumors.
[17704239] J Nucl Med 48(9): 1468-81 (2007)
2007  
17
Partial-volume effect in PET tumor imaging.
[17504879] J Nucl Med 48(6): 932-45 (2007)
2007  
18
Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.
[17204723] J Nucl Med 48 Suppl 1(-): 78S-88S (2007)
2007  
19
PET-based treatment planning in radiotherapy: a new standard?
[17204722] J Nucl Med 48 Suppl 1(-): 68S-77S (2007)
2007  
20
Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma.
[17204721] J Nucl Med 48 Suppl 1(-): 58S-67S (2007)
2007  
21
Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen.
[17204720] J Nucl Med 48 Suppl 1(-): 45S-57S (2007)
2007  
22
Monitoring cancer treatment with PET/CT: does it make a difference?
[17204719] J Nucl Med 48 Suppl 1(-): 36S-44S (2007)
2007  
23
Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.
[17204718] J Nucl Med 48 Suppl 1(-): 28S-35S (2007)
2007  
24
Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
[17204717] J Nucl Med 48 Suppl 1(-): 19S-27S (2007)
2007  
25
Screening for cancer with PET and PET/CT: potential and limitations.
[17204716] J Nucl Med 48 Suppl 1(-): 4S-18S (2007)
2006  
26
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
[16741317] J Nucl Med 47(6): 1059-66 (2006)
2006  
27
18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
[16741296] J Nucl Med 47(6): 901-3 (2006)
2006  
28
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.
[16644760] J Nucl Med 47(5): 885-95 (2006)
2006  
29
PET evaluation of lung cancer.
[16513615] J Nucl Med 47(3): 451-69 (2006)
2005  
30
Oncologic imaging in gynecologic malignancies.
[16269598] J Nucl Med 46(11): 1842-50 (2005)
2005  
31
Use of PET for monitoring cancer therapy and for predicting outcome.
[15937310] J Nucl Med 46(6): 983-95 (2005)
2005  
32
18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
[15937306] J Nucl Med 46(6): 958-63 (2005)
2004  
33
Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT.
[14736839] J Nucl Med 45 Suppl 1(-): 82S-95S (2004)
2004  
34
PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies.
[14736838] J Nucl Med 45 Suppl 1(-): 72S-81S (2004)
2004  
35
Why most PET of lung and head-and-neck cancer will be PET/CT.
[14736837] J Nucl Med 45 Suppl 1(-): 66S-71S (2004)
2004  
36
PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.
[14734674] J Nucl Med 45(1): 56-68 (2004)
2003  
37
Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors.
[12902422] J Nucl Med 44(8): 1301-14 (2003)
2003  
38
18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.
[12571214] J Nucl Med 44(2): 224-39 (2003)
2000  
39
The diagnostic utility of the lognormal behavior of PET standardized uptake values in tumors.
[11037996] J Nucl Med 41(10): 1664-72 (2000)
2000  
40
A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer.
[10914907] J Nucl Med 41(7): 1177-89 (2000)
1999  
41
Potential applications of PET imaging in developing novel cancer therapies.
[10452317] J Nucl Med 40(6): 995-1002 (1999)
1999  
42
Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
[10210218] J Nucl Med 40(4): 591-603 (1999)
1998  
43
Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine.
[9669415] J Nucl Med 39(7): 1302-5 (1998)
2000  
44
FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
[10855626] J Nucl Med 41(6): 1010-5 (2000)
1999  
45
Oncological applications of FDG PET imaging.
[10520713] J Nucl Med 40(10): 1706-15 (1999)
1991  
46
The applications of PET in clinical oncology.
[2013803] J Nucl Med 32(4): 623-48; discussion 649-50 (1991)
2003  
47
Clinical role of FDG PET in evaluation of cancer patients.
[12640150] Radiographics 23(2): 315-40; quiz 533 (2003)
1999  
48
Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants.
[9925392] Radiographics 19(1): 61-77; quiz 150-1 (1999)
2004  
49
Clinical applications of PET in oncology.
[15044750] Radiology 231(2): 305-32 (2004)
2009  
50
Measuring response with FDG-PET: methodological aspects.
[19357228] Oncologist 14(4): 369-77 (2009)
2008  
51
Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow.
[18586918] Oncologist 13(6): 631-44 (2008)
2010  
52
Hypoxia PET/CT imaging: implications for radiation oncology.
[20927017] Q J Nucl Med Mol Imaging 54(5): 500-9 (2010)
2004  
53
2007  
54
Somatostatin receptor PET imaging with Gallium-68 labeled peptides.
[17464267] Q J Nucl Med Mol Imaging 51(3): 244-50 (2007)
2007  
55
2009  
56
Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.
[19293767] Q J Nucl Med Mol Imaging 53(2): 193-200 (2009)
2008  
57
Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging.
[18235421] Q J Nucl Med Mol Imaging 52(1): 50-65 (2008)
2010  
58
Tumor pH and its measurement.
[20660380] J Nucl Med 51(8): 1167-70 (2010)
2010  
59
Proton therapy dosimetry using positron emission tomography.
[21160579] World J Radiol 2(4): 135-42 (2010)
2010  
60
Methodological considerations in quantification of oncological FDG PET studies.
[19936745] Eur J Nucl Med Mol Imaging 37(7): 1408-25 (2010)
2010  
61
FDG PET/CT in carcinoma of unknown primary.
[19882152] Eur J Nucl Med Mol Imaging 37(3): 635-44 (2010)
2011  
62
FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations.
[21611100] World J Clin Oncol 2(5): 229-36 (2011)
2011  
63
Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging.
[21174096] Eur Radiol 21(3): 548-54 (2011)
2009  
64
Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis.
[18925401] Eur Radiol 19(3): 731-44 (2009)
2007  
65
Case report: PET/CT, a cautionary tale.
[17683560] BMC Cancer 7(-): 147 (2007)
2010  
66
Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy.
[21147377] Semin Ultrasound CT MR 31(6): 496-505 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


  • Durchführung der Ganzkörper-F-18-FDG-PET und -PET/CT bei Kindern mit onkologischen Erkrankungen


  • Neubildung (PET)

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia